Bauer Jake 4

What Happened
Jake Bauer, a director of Immunovant, was granted equity awards on April 7, 2026: 13,880 restricted stock units (RSUs) and an award covering 7,061 option-linked shares (both reported as acquired at $0.00). These are compensation grants (not open-market purchases or sales) and carry no immediate cash cost to the reporting person.

Key Details

• Transaction date: 2026-04-07; Form 4 filed 2026-04-09.
• Grants: 13,880 RSUs and 7,061 option-linked shares, acquisition price reported $0.00.
• Vesting: Both the RSUs and the shares underlying the options vest in full on April 1, 2027, subject to Bauer’s continuous service through that date (see footnotes).
• Post-transaction holdings: Not specified in the filing.
• Notable footnotes:
  • RSUs represent a contingent right to receive one share per unit on vesting; the reporting person may elect to defer settlement of vested RSUs subject to Rule 409A.
  • The option-linked award vests on the same schedule; the filing does not state exercise price or whether any immediate sale/cashless exercise will occur.

Context
These are standard equity compensation awards to a director rather than an open-market purchase or sale. Grants at $0.00 reflect that shares/units were awarded, not bought; they typically vest over time and therefore do not necessarily indicate immediate bullish trading by the insider.